A phase II feasibility study of carboplatin and nab‐paclitaxel for advanced non‐small cell lung cancer patients with interstitial lung disease (YLOG0114)

BACKGROUND: A standard treatment regimen for advanced non‐small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) has not been established since most clinical trials exclude such patients because of the high risk of acute exacerbation of ILD. This study aimed to prospectively in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakashita, Hiroyuki, Uchibori, Ken, Jin, Yasuto, Tsutsui, Toshiharu, Honda, Takayuki, Sakakibara, Rie, Mitsumura, Takahiro, Nukui, Yoshihisa, Shirai, Tsuyoshi, Masuo, Masahiro, Suhara, Kozo, Furusawa, Haruhiko, Yamashita, Takaaki, Ohba, Takehiko, Saito, Kazuhito, Takagiwa, Jun, Miyashita, Yoshihiro, Inase, Naohiko, Miyazaki, Yasunari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058300/
https://www.ncbi.nlm.nih.gov/pubmed/35322551
http://dx.doi.org/10.1111/1759-7714.14376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058300/
https://www.ncbi.nlm.nih.gov/pubmed/35322551
http://dx.doi.org/10.1111/1759-7714.14376

Ejemplares similares